Home › Hemianopsia › NCT07185971

PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery

PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss

Who can join

Ages 21 to 80 · All sexes

Inclusion Criteria:

* This study will include patients at least 6 months after the CVA or TBI or brain surgery event and up to ten (10) years after onset
* The patients shall have a definitive diagnosis of homonymous hemianopia or quadrantanopia or generalized constriction.

Exclusion Criteria:

* Presence of any physical, neurological, or mental disability that would interfere with receiving the therapy.
* Concurrent use of another visual therapy
* Concurrent use of medications judged to affect training (amphetamines, dopamine, etc.)
* Presence of ocular or neurological conditions that would interfere with training or cause a visual impairment including no residual vision, disorders of the eye, non-optic nerve heteronymous visual field defects
* Insufficient fixation ability
* Use of life supporting external medical device such as infusion pumps, ventricular assist devices, etc.
* Presence of active implantable medical device including but not limited to cardiac pacemakers, defibrillators, nerve stimulators, cochlear implants, etc.
* Subjects with known photosensitive epilepsy.
* Subjects with chronic active infections on the head and face should be excluded from the study
* Patients with known immune disorders for whom an infection could be life threatening should be excluded from the study.

About the study

This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery. The PAVE regimen involves the use of a virtual reality headset to deliver visual stimulation to subjects diagnosed with visual field loss.

The primary objective is to demonstrate that there is an improvement in the visual field after use of the PAVE therapy over a period of eight weeks with three sessions per week. The primary outcome is an increase in visual field area as measured with Goldmann-type kinetic perimetry.

The secondary outcome will be demonstration that the subjective assessment of visual function using the National Eye Institute Visual Function Questionnaire (NEI-VFQ) is better after PAVE therapy when compared to before therapy.

The participants will visit the investigators office at the start of the study to establish a baseline for visual field size and visual field function. The subject will use PAVE in the office or at home three times per week for eight weeks. There will be twenty four therapy sessions in total. At four weeks the subject will visit the office and have perimetry measurements. At eight weeks the subject will visit the office and have perimetry measurements and complete the NEI-VFQ survey. Four weeks after the completion of the therapy sessions a follow up visit will take place where visual field measurement using kinetic perimetry and NEI-VFQ will be administered.

What is being tested

• PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display (device)

Sponsor: NeuroAEye LLC · Participants: 20 · Started: Mar 16, 2026

Contact the study team

• Michael Lynch, BSME · Phone: 315-730-9842
• Paige Clinical Study Coordinator · Phone: 319-366-3500

Official record on ClinicalTrials.gov — NCT07185971

Locations in the U.S.

Conditions

• Hemianopsia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.